Laboratory biomarkers and frailty: presentation of the FRAILOMIC initiative

Giuseppe Lippi; Pidder Jansen-Duerr; Jose Viña; Anna Durrance-Bagale; Imad Abugessaisa; David Gomez-Cabrero; Jesper Tegnér; Johannes Grillari; Jorge Erusalimsky; Alan Sinclair; Leocadio Rodriguez-Manãs; on behalf of the FRAILOMIC consortium

doi:10.1515/cclm-2015-0147

Published by De Gruyter March 14, 2015

Laboratory biomarkers and frailty: presentation of the FRAILOMIC initiative

Giuseppe Lippi , Pidder Jansen-Duerr , Jose Viña , Anna Durrance-Bagale , Imad Abugessaisa , David Gomez-Cabrero , Jesper Tegnér , Johannes Grillari , Jorge Erusalimsky , Alan Sinclair , Leocadio Rodriguez-Manãs and on behalf of the FRAILOMIC consortium

From the journal Clinical Chemistry and Laboratory Medicine (CCLM)

https://doi.org/10.1515/cclm-2015-0147

Showing a limited preview of this publication:

Keywords: ageing; biomarkers; frailty; sarcopenia

Corresponding author: Prof. Giuseppe Lippi, U.O. Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Via Gramsci 14, 43126 Parma, Italy, Phone: +39 0521 703050, Fax: +39 0521 703791, E-mail: glippi@ao.pr.it; ulippi@tin.it.

References

1. Rodríguez-Mañas L, Sinclair AJ. Frailty: the quest for new domains, clinical definitions and subtypes. Is this justified on new evidence emerging? J Nutr Health Aging 2014;18:92–4.10.1007/s12603-013-0433-9Search in Google Scholar

2. Rodríguez-Artalejo F, Rodríguez-Mañas L. The frailty syndrome in the public health agenda. J Epidemiol Community Health 2014;68:703–4.10.1136/jech-2014-203863Search in Google Scholar

3. Laosa O, Alonso C, Castro M, Rodriguez-Manas L. Pharmaceutical interventions for frailty and sarcopenia. Curr Pharm Des 2014;20:3068–82.10.2174/13816128113196660705Search in Google Scholar

4. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013;381:752–62.10.1016/S0140-6736(12)62167-9Search in Google Scholar

5. Lippi G, Plebani M. Biomarker research and leading causes of death worldwide: a rather feeble relationship. Clin Chem Lab Med 2013;51:1691–3.10.1515/cclm-2013-0210Search in Google Scholar PubMed

6. Plebani M. From symptoms to biomarkers: a change of paradigm. Clin Chem Lab Med 2014;52:1513–5.10.1515/cclm-2014-0910Search in Google Scholar PubMed

7. Lippi G, Sanchis-Gomar F, Montagnana M. Biological markers in older people at risk of mobility limitations. Curr Pharm Des 2014;20:3222–44.10.2174/13816128113196660697Search in Google Scholar PubMed

8. Fernández-Garrido J, Ruiz-Ros V, Buigues C, Navarro-Martinez R, Cauli O. Clinical features of prefrail older individuals and emerging peripheral biomarkers: a systematic review. Arch Gerontol Geriatr 2014;59:7–17.10.1016/j.archger.2014.02.008Search in Google Scholar PubMed

9. Plebani M. Harmonization in laboratory medicine: the complete picture. Clin Chem Lab Med 2013;51:741–51.10.1515/cclm-2013-0075Search in Google Scholar PubMed

10. Hens K, Berth M, Armbruster D, Westgard S. Sigma metrics used to assess analytical quality of clinical chemistry assays: importance of the allowable total error (TEa) target. Clin Chem Lab Med 2014;52:973–80.10.1515/cclm-2013-1090Search in Google Scholar PubMed

Received: 2015-2-11

Accepted: 2015-2-18

Published Online: 2015-3-14

Published in Print: 2015-9-1

Laboratory biomarkers and frailty: presentation of the FRAILOMIC initiative

References

Journal and Issue

Articles in the same Issue